New Study: Weight-Loss Drugs May Help Heart Recovery After Attacks
A recent study suggests that a well-known class of weight-loss medications could help prevent serious heart issues after a heart attack. These drugs work by improving blood flow in small blood vessels that often stay blocked even after emergency treatment. The research was published in Nature Communications and was conducted by teams from the University of Bristol and University College London.
How It Works
The study identified a pathway linking the brain, gut, and heart. The medications, which mimic a hormone called GLP-1, play a crucial role in regulating both blood sugar levels and appetite. According to Dr. Svetlana Mastitskaya, the lead author of the study, nearly half of heart attack patients experience a condition called “no-reflow.” This occurs when tiny blood vessels in the heart remain narrowed after the main artery is cleared, which can lead to further complications.
These complications increase the risk of heart failure and can lead to death within a year. However, the researchers believe that GLP-1 medications could potentially prevent this issue.
Mechanism Behind the Benefits
When GLP-1 is released, whether naturally or via medication, it sends signals to the brain, which in turn advises the heart to activate special potassium channels in a type of cell known as pericytes. This allows these small blood vessels to widen and improves blood flow to the heart muscle, aiding recovery.
The findings indicate that existing GLP-1 drugs, which are already prescribed for type 2 diabetes and obesity, could be used as emergency treatments during or just after a heart attack, particularly to minimize tissue damage.
Need for Further Research
While the study has shown promising results in animal models, the researchers acknowledge that more work is needed. Clinical trials are essential to confirm if the same brain-gut-heart pathway works effectively in humans.
Additionally, while this study highlights the potential immediate benefits of GLP-1 medications during a heart attack, it does not clarify whether long-term use of these drugs provides any ongoing protective effects.
This important research was funded primarily by the British Heart Foundation, paving the way for potential new uses of existing medications.
